Age: 37.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: X-ray
Clinical narrative: Watering eyes/recurrent eyes watery; Runny nose/recurrent runny nose; Drop in blood pressure; Seasonal allergy; Postural orthostatic tachycardia syndrome; tachycardia syndrome; Psoriasis flare-up/flare off of psoriasis/Psoriasis flare-up/Psoriasis flare-up -Worsened; Scalp swelling/ scalp swelling - Worsened/swollen scalp; Knee swelling; Psoriatic arthritis aggravated/-Worsened/flare off of psoriatic arthritis; Itchy scalp/Itchy scalp -Worsened/Localised itching -Worsened/itch on back, arms, knees; Local swelling / Local swelling -Worsened/swollen  back; Scalp pain/Scalp pain Worsened/painful scalp; Pain back/Pain back - worsened/painful back; Painful arm/Painful arm - worsened; Painful knee/Painful knee Worsened; Swollen arm /Swollen arm -worsened; This is a non-interventional study report based on the information received by Pfizer (Mfr Control No. 21K-163-3740568-00)  received from a contactable consumer (patient).   A 37 yearsold male patient received bnt162b2 (BNT162B2), dose 1 intramuscular on 25Mar2021 (at the age of 37 years old) (Batch/Lot number was not reported) as SINGLE DOSE for covid-19 immunisation; adalimumab (HUMIRA), subcutaneous from 2017 (Batch/Lot number was not reported) to 25Mar2021, at unknown dose weekly[1 in 2 wk] for Moderate to Severe Chronic Plaque Psoriasis . Medical history included non tobacco, abstains from alcohol,  Klippel feil syndrome,  spinal fusion surgery, seasonal allergy, postural orthostatic tachycardia syndrome from 2017 to an unknown date , blood pressure decreased from 2017 to an unknown date. The patient concomitant medications were not reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The patient experienced psoriatic arthritis aggravated/-worsened/ flare off of psoriatic arthritis (medically significant) on 25Mar2021, postural orthostatic tachycardia syndrome  on an unspecified date, tachycardia syndrome  on an unspecified date. psoriasis flare up/ Psoriasis flare up -Worsened  on 25Mar2021, scalp swelling/ scalp swelling -  worsened/ painful scalp on 25Mar2021,  knee swelling on 25Mar2021,  watering eyes/recurrent eyes watery on an unspecified date,  runny nose/recurrent runny nose  on an unspecified date, drop in blood pressure on an unspecified date,  seasonal allergy on an unspecified date,  itchy scalp/itchy scalp -worsened/localised itching -worsened/ itch on back, arms, knees  on 25Mar2021, local swelling / local swelling -worsened/ swollen  back on 25Mar2021, scalp pain/scalp pain worsened/painful scalp on 25Mar2021, pain back/pain back - worsened/ painful back 25Mar2021, painful arm/painful arm - worsened on 25Mar2021,painful knee/painful knee worsened on 25Mar2021, swollen arm /swollen arm -worsened on 25Mar2021,  psoriasis flare-up/psoriasis flare-up -worsened on 25Mar2021. The patient underwent lab tests and procedures which included blood pressure measurement: drop  on 2017 blood test: normal o an unspecified date, magnetic resonance imaging: normal  on 2018,  x-ray: normal on 2008. The action taken in response to the event for adalimumab was permanently withdrawn on 25Mar2021(also reported as dose not changed). The clinical outcome of the event Psoriatic arthritis aggravated, Psoriasis flare-up, Scalp swelling, Knee swelling, Itchy scalp, Local swelling , Scalp pain, Painful arm, Knee pain, Swollen arm, Psoriasis flare-up    was not recovered, while Postural orthostatic tachycardia syndrome, tachycardia syndrome, Watering eyes, Runny nose, Drop in blood pressure recovered, and the remaining events was unknown.  Causality for Humira (Adalimumab) the reporter's causality for the event(s) of postural orthostatic tachycardia syndrome, swollen scalp, swollen knee, recurrent eyes watery, recurrent runny nose, blood pressure drop, seasonal allergies, itch on scalp, itch on back, arms, knees, swollen back, flare off of psoriasis, flare off of psoriatic arthritis, painful scalp, painful back, painful arms, painful knees, swollen arm and recurrent congestion with humira (adalimumab) was no reasonable possibility.  The reporter assessment of the causal relationship of the (enter the event term) with the suspect product was not provided at the time of this report.  Since no determination has been received, the case is managed based on the company causality assessment.     Information on the lot/batch number has been requested.; Sender's Comments: Based on the available information, the reported events are attributed to underlying or intercurrent medical conditions which were unlikely related to BNT162B2 vaccine.